Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rth2.12395 http://scihub22266oqcxt.onion/10.1002/rth2.12395 C7280574!7280574!32838109     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Res+Pract+Thromb+Haemost 2020 ; 4 (6): 984-96 Nephropedia Template TP {{tp|p=32838109|t=2020. Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID?19: Study design of the phase IIa STARS trial |pdf=|usr=}}{{32838109}} gab.com Text Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID 19: Study design of the phase IIa STARS trial JO: Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32838109 #FOAvip Background: The coronavirus disease 2019 (COVID?19) pandemic has caused a large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non?COVID?19) demonstrated improvement in pulmonary function in patients ARDS using fibrinolytic therapy. A follow?up trial using the widely available tissue?type plasminogen activator (t?PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient population. Objective: To describe the design and rationale of a phase IIa trial to evaluate the safety and efficacy of alteplase treatment for moderate/severe COVID?19?induced ARDS. Patients/Methods: A rapidly adaptive, pragmatic, open?label, randomized, controlled, phase IIa clinical trial will be conducted with 3 groups: intravenous alteplase 50 mg, intravenous alteplase 100 mg, and control (standard?of?care). Inclusion criteria are known/suspected COVID?19 infection with PaO2/FiO2 ratio <150 mm Hg for > 4 hours despite maximal mechanical ventilation management. Alteplase will be delivered through an initial bolus of 50 mg or 100 mg followed by heparin infusion for systemic anticoagulation, with alteplase redosing if there is a >20% PaO2/FiO2 improvement not sustained by 24 hours. Results: The primary outcome is improvement in PaO2/FiO2 at 48 hours after randomization. Other outcomes include ventilator? and intensive care unit?free days, successful extubation (no reintubation ?3 days after initial extubation), and mortality. Fifty eligible patients will be enrolled in a rapidly adaptive, modified stepped?wedge design with 4 looks at the data. Conclusion: Findings will provide timely information on the safety, efficacy, and optimal dosing of t?PA to treat moderate/severe COVID?19?induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634). Twit Text FOAVip Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID 19: Study design of the phase IIa STARS trial ????Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32838109 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32838109 #FOAvip English Wikipedia <ref>{{Cite pmid|32838109}}</ref> Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID?19: Study design of the phase IIa STARS trial #MMPMID32838109 Moore HB; Barrett CD; Moore EE; Jhunjhunwala R; McIntyre RC; Moore PK; Wang J; Hajizadeh N; Talmor DS; Sauaia A; Yaffe MB Res Pract Thromb Haemost 2020[Aug]; 4 (6): 984-96 PMID32838109show ga Background: The coronavirus disease 2019 (COVID?19) pandemic has caused a large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non?COVID?19) demonstrated improvement in pulmonary function in patients ARDS using fibrinolytic therapy. A follow?up trial using the widely available tissue?type plasminogen activator (t?PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient population. Objective: To describe the design and rationale of a phase IIa trial to evaluate the safety and efficacy of alteplase treatment for moderate/severe COVID?19?induced ARDS. Patients/Methods: A rapidly adaptive, pragmatic, open?label, randomized, controlled, phase IIa clinical trial will be conducted with 3 groups: intravenous alteplase 50 mg, intravenous alteplase 100 mg, and control (standard?of?care). Inclusion criteria are known/suspected COVID?19 infection with PaO2/FiO2 ratio <150 mm Hg for > 4 hours despite maximal mechanical ventilation management. Alteplase will be delivered through an initial bolus of 50 mg or 100 mg followed by heparin infusion for systemic anticoagulation, with alteplase redosing if there is a >20% PaO2/FiO2 improvement not sustained by 24 hours. Results: The primary outcome is improvement in PaO2/FiO2 at 48 hours after randomization. Other outcomes include ventilator? and intensive care unit?free days, successful extubation (no reintubation ?3 days after initial extubation), and mortality. Fifty eligible patients will be enrolled in a rapidly adaptive, modified stepped?wedge design with 4 looks at the data. Conclusion: Findings will provide timely information on the safety, efficacy, and optimal dosing of t?PA to treat moderate/severe COVID?19?induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634). äStudy of alteplase for respiratory failure in severe acute respiratory(epmc).pdf DeepDyve Pubget Overpricing